T-cell lymphoblastic lymphoma presenting with a large intrathoracic mass and pleural effusion in a 2-year-old girl: A case report

Jamila Sama1*, Vinod G2

1Physician Associate, Pediatric Hemato-Oncology, Maa Kauvery Hospital, Trichy, Tamil Nadu

2Senior Consultant, Pediatric Hemato-Oncology, Maa Kauvery Hospital, Trichy, Tamil Nadu

*Correspondence

Abstract

Background: T-cell lymphoblastic lymphoma (T-LBL) is a fast-growing blood cancer of childhood that typically presents as an anterior mediastinal mass. The mass can compress the central airways, and the rapid turnover of tumor cells can cause tumor lysis syndrome (TLS) even before chemotherapy is started (spontaneous TLS).

Case Presentation: A previously healthy 2-year-old girl presented after 10 days of poor oral intake and cough, followed by 2 to 3 days of fast breathing (tachypnea) and weight loss. Chest CT showed a large left intrathoracic mass (~13 × 9 cm) with shift of the mediastinum to the right and a left pleural effusion. Initial tests showed raised uric acid (13.59 mg/dL), phosphorus (6.41 mg/dL) and lactate dehydrogenase (LDH, 2246 U/L). An intercostal chest drain (ICD) was placed under local anesthesia, which gave immediate relief of breathing difficulty. Flow cytometry of the pleural fluid obtained during ICD insertion showed T-lymphoblasts and established the diagnosis of T-LBL, so a high-risk tissue biopsy was avoided. Treatment included hyperhydration, allopurinol, rasburicase, sevelamer and oral prednisolone. Uric acid and phosphorus levels normalized within 48 hours, and the chest radiograph showed marked regression of the mass by Day 6. She was discharged on Day 7 and was scheduled to continue induction chemotherapy on follow-up.

Conclusion: Pleural fluid analysis offers a safe diagnostic route in children with a large chest mass with pleural effusion. Prompt treatment of spontaneous TLS before chemotherapy helped to keep her kidney function normal.

Keywords: T-cell lymphoblastic lymphoma; Intrathoracic mass; Pleural effusion; Tumor lysis syndrome; Pediatric oncology; Rasburicase

Background

Lymphoblastic lymphoma (LBL) accounts for about 25% to 35% of pediatric non-Hodgkin lymphomas, and most cases (70% to 80%) are of T-cell lineage [1,2]. It characteristically presents as an anterior mediastinal mass. Children often present in acute respiratory distress because of airway compression or an associated pleural or pericardial effusion [1,2]. Procedural sedation or general anesthesia carries a serious risk of complete airway collapse in these patients, so choosing a safe diagnostic strategy is as important as making the diagnosis itself. T-LBL grows rapidly and can cause tumor lysis syndrome (TLS), a metabolic emergency caused by rapid breakdown of tumor cells, even before chemotherapy is started [3]. TLS that occurs before any cytotoxic treatment is called spontaneous TLS. Here, we report a 2-year-old girl with a large intrathoracic mass, a left pleural effusion and spontaneous TLS before treatment. The diagnosis was made safely by flow cytometry of pleural fluid obtained during ICD insertion, which avoided a high-risk tissue biopsy.

Case Presentation

A previously healthy 2-year-old girl was brought to our hospital by her family. She had poor feeding (solids and liquids) and upper respiratory symptoms (cough and cold) for 10 days, followed by 2 to 3 days of tachypnea with chest retractions and an estimated weight loss of 1 to 2 kg. She had no fever, vomiting or diarrhea. She was born at full term (birth weight 2.8 kg), was fully vaccinated for her age and had normal growth and development. She had no past medical history, no previous hospital admissions, no regular medications and no tuberculosis exposure. Her parents were non-consanguineous. A non-contrast chest CT scan at the referring hospital showed a large intrathoracic mass in the left chest causing mass effect, displacing the trachea, mediastinum and heart to the right, along with a moderate left pleural effusion. She was transferred to our hospital on the same day (Day 0). On arrival, she was conscious and alert (Glasgow Coma Scale 15/15) and afebrile. Her respiratory rate was 65 to 70 breaths/min, SpO2 97% on room air, heart rate 140 beats/min, blood pressure 90/60 mmHg, and capillary refill time under 3 seconds. Examination showed subcostal and intercostal retractions, decreased breath sounds over the left hemithorax and rightward displacement of the cardiac apex. Bedside ultrasound confirmed a left chest mass with an adjacent fluid collection about 3.5 cm deep and mediastinal shift. Her weight was 9.9 kg, length 87 cm and body surface area 0.49 m2.

Investigations

Radiological Findings

Fig (1): (A) Chest radiograph on Day 0 (29-Oct-26) after ICD placement, showing left hemithorax opacification and rightward cardiac and mediastinal shift. (B) Follow-up radiograph on Day 6 (04-Nov-26) after prednisolone therapy, showing marked regression of the left chest mass and clear left lung fields.

  • External CT review: Left thoracic mass measuring ~13 × 9 cm and encasing the pericardium, moderate left pleural effusion, left lung atelectasis/consolidation and enlarged left axillary lymph nodes.
  • Chest radiograph: Widened mediastinum with rightward displacement of the heart (Fig 1A).

Laboratory Investigations

Blood test results, including serum lactate dehydrogenase (LDH), are summarized in Table 1.

Table 1: Laboratory results during admission

Test Day 0 Day 2 Day 3 Day 7 (discharge)
Hemoglobin (g/dL) 13.3 – – 13.1
Total leukocyte count (/mm3) 8,680 – – 8,490
Platelets (/mm3) 408,000 – – 416,000
Uric acid (mg/dL) 13.59 0.75 1.09 1.40
Phosphorus (mg/dL) 6.41 3.92 4.03 4.02
Potassium (mmol/L) 4.76 4.43 4.63 4.81
Creatinine (mg/dL) 0.44 0.31 0.32 0.30
Calcium (mg/dL) 10.48 – 9.91 –
Bicarbonate (mmol/L) 12.6 – 23.8 –
LDH (U/L) 2246 – – –

Other baseline laboratory values were: blood urea 25 mg/dL, AST 80 U/L, ALT 18 U/L, total bilirubin 0.60 mg/dL, PT 11.4 s, APTT 30.3 s and INR 1.10. The peripheral blood film showed normocytic red cells, mild monocytosis and no circulating lymphoblasts. Venous blood gas on Day 1 showed pH 7.36, pCO2 36 mmHg and lactate 2.8 mmol/L.

Pleural Fluid Analysis

The pleural fluid obtained during ICD insertion was viscous and hemorrhagic. The cell count was 286,915 cells/mm3 (98% mononuclear cells, 2% polymorphs), with 55,000 RBCs/mm3. Flow cytometry showed that 75% of the cells were blasts with a T-cell immunophenotype: CD45 (moderate to bright), variable CD34, CD38, CD7, CD5, bright CD1a, CD4 (moderate to bright), CD8 (moderate) and bright cytoplasmic CD3. Surface CD3 and TCR alpha/beta were negative. B-cell markers (CD19, CD10, CD20, CD22, CD79a) and myeloid markers (MPO, CD13, CD33, CD117, CD64, CD14, CD15, HLA-DR) were all negative. The pathology report described the findings as T-cell acute lymphoblastic leukemia (T-ALL)/lymphoma. Considering the large intrathoracic mass with effusion, normal blood counts and no circulating blasts, the final diagnosis was T-LBL.

Management

The patient was admitted to the Pediatric Intensive Care Unit (PICU) for close monitoring. Because of her large tumor burden and the high risk of airway compression, procedural sedation and endotracheal intubation were considered dangerous, and difficult airway precautions were set up with a pediatric intensivist on standby.

  • Draining the fluid: On the evening of Day 0, an ICD was placed in the left 7th intercostal space along the midaxillary line under ultrasound guidance, at the site of maximum fluid depth. Local anesthesia with minimal sedation was used, with supplemental oxygen (SpO2 before the procedure was about 92% on room air). Hemorrhagic fluid was drained, and a sample collected during the procedure was sent for cell count, cytology and flow cytometry. The drain was removed once drainage had stopped.
  • Supportive care: Empiric IV ceftriaxone, vitamin K and tranexamic acid were started (tranexamic acid was stopped on Day 2 after re-evaluation). Oxygen was stepped down from face mask to nasal cannula, and she maintained normal saturations on room air by Day 3.
  • Treating TLS: Hyperhydration was started at double maintenance. TLS treatment included oral allopurinol to control uric acid level and sevelamer to control phosphate levels. A single dose of IV rasburicase (1.5 mg) was given on Day 1. IV furosemide was given to maintain urine output. Urine output stayed good (3.7 to 6.6 mL/kg/hr) with a positive fluid balance. Serum electrolytes, uric acid, phosphorus and creatinine were checked every 12 to 24 hr.
  • Steroids: Oral prednisolone was started at a low dose on Day 1, after the pleural fluid sample had been collected. The dose was increased gradually once the flow cytometry result was confirmed, to promote tumor cytoreduction.

Outcome and Follow-up

The patient improved steadily. Her respiratory rate fell from 65 to 70 breaths/min on admission to 28 breaths/min by Day 3, with SpO2 of 97% on room air. The biochemical features of TLS resolved quickly: serum uric acid fell from 13.59 to 0.75 mg/dL within 48 hours, and phosphorus returned to normal by Day 2 (3.92 mg/dL). Serum creatinine stayed within normal limits throughout her hospital stay, and renal replacement therapy was not needed. Ultrasound on Day 3 showed minimal residual left pleural fluid (0.99 cm deep), with complete resolution by Day 6. A repeat chest radiograph on Day 6 showed marked regression of the mass and clear left lung fields (Figure 1B). She had mild vomiting on Day 4, and mild cough, abdominal discomfort and constipation on Day 6, all of which settled with supportive treatment.

She was discharged home on Day 7 in stable condition on oral prednisolone, allopurinol, sevelamer, a proton pump inhibitor and a laxative. Discharge labs showed Hb 13.1 g/dL, uric acid 1.40 mg/dL and phosphorus 4.02 mg/dL. She was scheduled to continue induction chemotherapy on follow-up.

Discussion

  • Diagnosis – T-LBL and T-ALL share the same T-cell phenotype and differ mainly in bone marrow involvement, with fewer than 25% marrow blasts in T-LBL [1,2]. A large intrathoracic mass with effusion, normal blood counts and no circulating blasts fits T-LBL, although the pathology report used the term T-ALL/lymphoma.
  • Pleural fluid as a safe diagnostic route – Draining a pleural effusion under local anesthesia relieves breathlessness and provides diagnostic fluid [4]. In young children with a large chest mass, general anesthesia or deep sedation can cause airway collapse, so ICD insertion under local anesthesia avoided this risk and a tissue biopsy. The fluid was collected before steroids, which can quickly kill lymphoblasts and reduce diagnostic yield.
  • Spontaneous TLS before chemotherapy – A very high LDH (2246 U/L) and uric acid (13.59 mg/dL) reflect a large tumor burden and a high risk of TLS [3]. Early hyperhydration, rasburicase and sevelamer brought uric acid and phosphorus to normal within 48 hours with normal creatinine. Because prednisolone can itself trigger tumor lysis, TLS treatment and 12- to 24-hourly monitoring continued alongside it.

Conclusion

Young children with tachypnea, weight loss and a large chest mass should be managed as an acute airway emergency. Pleural fluid flow cytometry is a reliable, low-risk alternative to surgical biopsy when the fluid is collected before steroid therapy. Spontaneous TLS can occur before treatment, and early hyperhydration, rasburicase and sevelamer helped to protect renal function in this child.

Reference

  1. Burkhardt B, Hermiston ML. Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities. Br J Haematol. 2019;185(6):1158-1170.
  2. Temple WC, Mueller S, Hermiston ML, et al. Diagnosis and management of lymphoblastic lymphoma in children, adolescents and young adults. Best Pract Res Clin Haematol. 2023;36(1):101449.
  3. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127(1):3-11.
  4. Pietsch JB, Whitlock JA, Ford C, et al. Management of pleural effusions in children with malignant lymphoma. J Pediatr Surg. 1999;34:635-638.
Kauvery Hospital